Financings in Brief: Orthofix
This article was originally published in The Gray Sheet
Executive SummaryOrthofix: Announces its intent to expand by 36% its holding in Novamedix, developer of the A-V Impulse System foot-pump for prevention of deep vein thrombosis. Orthofix' acquisition of the additional interest, expected to take place in August, will bring its stake in Novamedix to 80%. The announcement coincides with a decision in the London Patents County Court that NDM(UK) Ltd., marketer of the Act One Foot Pump, had infringed a Novamedix patent and had committed "passing off" by using abstracts of clinical studies in promotional literature for Act One without indicating that the studies related to the A-V Impulse System...
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.